Comera Life Sciences Inc has agreed to go public through a merger with OTR Acquisition Corp (NASDAQ:OTRA), a blank-check company.
- The combined company will have an initial equity value of about $258.4 million. The companies said it would provide about $107 million in gross cash proceeds.
- All 12.6 million shares will be issued to Comera stockholders at an implied value of $10 per share.
- The transaction also includes a potential earn-out to Comera shareholders, including 3.15 million more shares.
- The SPAC is led by investor and entrepreneur Nicholas J. Singer, who serves as chairman and CEO.
- After the transaction closes, Jeff Hackman, Comera’s CEO, will lead the combined company.
- Woburn, Massachusetts-based Comera Life, is developing new biologic medicines to improve safety and convenience for patients, switching from intravenous to subcutaneous injections.
- Comera applies its formulation platform, SQore, to develop a portfolio of proprietary subcutaneous (SQ) therapeutics.
- Comera will also continue collaborating with pharmaceutical and biotechnology companies, applying its SQore platform to partners’ biologic medicines to deliver enhanced formulations that facilitate self-injectable care.
- The merger will close in Q2 FY22.
- Price Action: OTRA shares are trading 0.13% higher at $10.17 during the market session on the last check Monday.
